Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The smooth progress of project-based contracts, the launch of operations at newly contracted SPD facilities, expansion of services at existing facilities, the introduction of fully prepared foods, small-scale M&A and new store openings contributed to higher revenue and profit. These gains were partly offset by lower demand for equipment renewals, the deferral of price negotiations with manufacturers to the following quarter and beyond, higher business operating costs due to inflation and other factors, revisions to pharmacy reimbursement rates, and a decline in prescription volumes due to the low level of infectious disease activity.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥176,361 million (YoY +8.0%) |
| Operating profit | ¥2,784 million (YoY -5.7%) |
| Ordinary income | ¥3,383 million (YoY +9.2%) |
| Profit attributable to owners of the parent | ¥2,090 million (YoY +2.9%) |
| Net income per share | ¥22.74 |
| Equity ratio | End of the current fiscal period 39.5 / End of previous period 39.2 |
| Total assets | ¥371,786 million |
| Net assets | ¥148,154 million |
| Full-year earnings forecast | Net Sales ¥740,000 million / Operating profit ¥26,000 million / Ordinary income ¥26,500 million / Profit attributable to owners of the parent ¥16,000 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥60 → ¥65 |
| Segment revenue | Segment Total Pack Produce Business / Net Sales ¥26,659 million / Year on year against the same period last year 11.9, Segment Medical Supply Business / Net Sales ¥131,991 million / Year on year against the same period last year 8.3, Segment Life Care Business / Net Sales ¥9,103 million / Year on year against the same period last year -1.4, Segment Dispensing Pharmacy Business / Net Sales ¥8,607 million / Year on year against the same period last year 3.1 |
| Segment profit | Segment Total Pack Produce Business / Segment profit ¥467 million / Year on year against the same period last year 0.4, Segment Medical Supply Business / Segment profit ¥1,088 million / Year on year against the same period last year -7.7, Segment Life Care Business / Segment profit ¥463 million / Year on year against the same period last year 11.4, Segment Dispensing Pharmacy Business / Segment profit ¥850 million / Year on year against the same period last year -8.3 |
| Depreciation and amortization | ¥1,375 million |
| Impairment loss | Amount Not applicable (no material impairment loss recognized) / Subject assets None |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥1 million / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥27 million, Item Other / Amount ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name ㈱ＭＹＮＳ / Excluded Number of companies 1 / Company name デルフィア㈱ |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 94,350,134 |
| Treasury Shares at Period-End | 2,699,500 |
| Factors Behind Changes in Business Performance | The smooth progress of project-based contracts, the launch of operations at newly contracted SPD facilities, expansion of services at existing facilities, the introduction of fully prepared foods, small-scale M&A and new store openings contributed to higher revenue and profit. These gains were partly offset by lower demand for equipment renewals, the deferral of price negotiations with manufacturers to the following quarter and beyond, higher business operating costs due to inflation and other factors, revisions to pharmacy reimbursement rates, and a decline in prescription volumes due to the low level of infectious disease activity. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales remained firm and, as measures to improve profitability in each business progressed, results were generally in line with plan. By business, revenue and profit were supported by the launch of operations at newly contracted SPD facilities, expansion of services at contracted facilities, small-scale M&A, new store openings and the introduction of fully prepared foods. These gains were partly offset by lower demand for equipment renewals, the deferral of price negotiations to the following quarter and beyond, higher costs, and the low level of infectious disease activity.